Ex-Kinetic Concepts CEO Catherine Burzik to chair VitaPath
This article was originally published in Clinica
Catherine Burzik, who previously headed up wound care firm Kinetic Concepts, has been appointed chair of genomic testing specialist VitaPath Genetics. Ms Burzik left Kinetic early this year (www.clinica.co.uk, 29 December 2011), following the completion of its acquisition by private equity firm Apax Partners in November (www.clinica.co.uk, 7 November 2011). She has also served as president of Applied Biosystems and held senior executive positions at Eastman Kodak and Johnson & Johnson. Privately-held VitaPath (Foster City, California) specialises in investigating the "vitanome", a subset of genomic information that plays an important role in how people metabolise vitamins. The company's goal is to identify how genetic variations in vitamin-responsive genes can lead to specific diseases, and how these can be treated with vitamin therapy. The firm's first test identifies women at the highest risk of having children with spina bifida, which may be prevented by taking folic acid before pregnancy; the product is expected to be offered in doctors' offices in 2013.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.